Department of Emergency Medicine, Medical College of Wisconsin, Milwaukee, WI, 53208, USA.
Department of Clinical Pharmacy, Syracuse VA Medical Center, Syracuse, NY, 13210, USA.
Harm Reduct J. 2024 Jun 7;21(1):114. doi: 10.1186/s12954-024-01028-4.
As the opioid public health crisis evolves to include fentanyl and other potent synthetic opioids, more patients are admitted to the hospital with serious complications of drug use and frequently require higher levels of care, including intensive care unit (ICU) admission, for acute and chronic conditions related to opioid use disorder (OUD). This patient population poses a unique challenge when managing sedation and ensuring adequate ventilation while intubated given their high opioid requirements. Starting a patient on medications such as buprenorphine may be difficult for inpatient providers unfamiliar with its use, which may lead to undertreatment of patients with OUD, prolonged mechanical ventilation and length of stay.
We developed a 7-day buprenorphine low dose overlap initiation (LDOI) schedule for patients with OUD admitted to the ICU (Table 1). Buprenorphine tablets were split by pharmacists and placed into pre-made blister packs as a kit to be loaded into the automated medication dispensing machine for nursing to administer daily. An internal quality review validated the appropriate dosing of split-dose tablets. To simplify order entry and increase prescriber comfort with this new protocol, we generated an order set within our electronic health record software with prebuilt buprenorphine titration orders. This protocol was implemented alongside patient and healthcare team education and counseling on the LDOI process, with follow-up offered to all patients upon discharge.
Here we report a series of 6 ICU patients started on buprenorphine using the LDOI schedule with split buprenorphine tablets. None of the 6 patients experienced precipitated withdrawal upon buprenorphine initiation using the LDOI schedule, and 5/6 patients were successfully extubated during the buprenorphine initiation. Four of six patients had a decrease in daily morphine milligram equivalents, with 3 patients transitioning to buprenorphine alone.
Initiating buprenorphine via LDOI was found to be successful in the development of a protocol for critically ill patients with OUD. We examined LDOI of buprenorphine in intubated ICU patients and found no events of acute precipitated withdrawal. This protocol can be used as a guide for other institutions seeking to start critically ill patients on medication treatment for OUD during ICU admission.
随着阿片类药物公共卫生危机的发展,包括芬太尼和其他强效合成阿片类药物在内,越来越多的患者因药物使用而出现严重并发症,并经常需要更高水平的治疗,包括入住重症监护病房(ICU)、急性和慢性阿片类药物使用障碍(OUD)相关疾病。对于这些患者,由于他们对阿片类药物的需求较高,在进行气管插管时,为他们管理镇静和确保充分通气是一个独特的挑战。对于不熟悉其使用方法的住院医生来说,开始给患者使用丁丙诺啡等药物可能很困难,这可能导致 OUD 患者治疗不足,机械通气时间延长和住院时间延长。
我们为入住 ICU 的 OUD 患者制定了 7 天丁丙诺啡低剂量重叠起始(LDOI)方案(表 1)。药剂师将丁丙诺啡片剂掰开并放入预先制作的泡罩包装中,制成试剂盒,装入自动化药物分配机,由护士每日给药。内部质量审查验证了分剂量片剂的适当剂量。为了简化医嘱录入并提高医嘱者对该新方案的舒适度,我们在电子病历软件中生成了一个包含预建丁丙诺啡滴定医嘱的医嘱集。该方案与患者和医疗团队的教育和咨询一起实施,所有患者出院后都提供后续服务。
我们在此报告了一系列使用 LDOI 方案和分拆丁丙诺啡片剂开始丁丙诺啡治疗的 6 例 ICU 患者。使用 LDOI 方案起始丁丙诺啡时,没有 6 例患者出现阿片类药物撤药反应,5/6 例患者在丁丙诺啡起始时成功脱机。6 例患者中有 4 例每日吗啡毫克当量减少,其中 3 例转为单独使用丁丙诺啡。
我们发现 LDOI 起始丁丙诺啡在制定 ICU 中患有 OUD 的危重症患者的方案方面是成功的。我们检查了气管插管的 ICU 患者中丁丙诺啡的 LDOI,未发现急性撤药反应的事件。该方案可作为其他机构在 ICU 住院期间为危重症患者开始阿片类药物治疗 OUD 提供指导。